BioNTech’s net profit falls sharply
BioNTech announced its balance sheet for the January-March period.
Consequently, the company’s net profit in the first quarter of this year decreased by 86 percent compared to the same period last year, to 502.2 million euros.
BioNTech announced a profit of 3.7 billion euros in the first quarter of 2022.
The company’s net profit per share, which was 14.24 euros in the first quarter of last year, fell to 2.05 euros in the same period this year.
BioNTech’s revenue, on the other hand, was down 80% in the first quarter of this year compared to the same period last year, to €1.3bn.
The company had revenue of 6.4 billion euros in the first quarter of 2022.
LOW INCOME FROM VACCINE SALES
In the statement made by the company, it was indicated that the variation in financial results was due to the company’s lower income from the supply and sale of vaccines against Covid-19 worldwide.
It was noted that revenue from Covid-19 vaccines is projected to be approximately €5 billion in 2023.
The World Health Organization (WHO) announced on May 5 that Covid-19 had ended as a “public health emergency” of international concern. (AA)
Source: Sozcu
Andrew Dwight is an author and economy journalist who writes for 24 News Globe. He has a deep understanding of financial markets and a passion for analyzing economic trends and news. With a talent for breaking down complex economic concepts into easily understandable terms, Andrew has become a respected voice in the field of economics journalism.
